US6462022B1 - Lisinopril compositions having large-particle DCPD - Google Patents
Lisinopril compositions having large-particle DCPD Download PDFInfo
- Publication number
- US6462022B1 US6462022B1 US09/962,429 US96242901A US6462022B1 US 6462022 B1 US6462022 B1 US 6462022B1 US 96242901 A US96242901 A US 96242901A US 6462022 B1 US6462022 B1 US 6462022B1
- Authority
- US
- United States
- Prior art keywords
- tablet
- dcpd
- lisinopril
- amount
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010007859 Lisinopril Proteins 0.000 title claims abstract description 73
- 229960002394 lisinopril Drugs 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 title claims abstract description 8
- 239000002245 particle Substances 0.000 title abstract description 21
- HECLRDQVFMWTQS-UHFFFAOYSA-N Dicyclopentadiene Chemical compound C1C2C3CC=CC3C1C=C2 HECLRDQVFMWTQS-UHFFFAOYSA-N 0.000 title description 54
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 238000007907 direct compression Methods 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 229960002429 proline Drugs 0.000 claims description 4
- 239000008247 solid mixture Substances 0.000 claims 3
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 abstract description 72
- 238000009472 formulation Methods 0.000 abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000007857 degradation product Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 15
- 229940072252 zestril Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 206010007559 Cardiac failure congestive Diseases 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- BFNXYSZBURSNHS-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BFNXYSZBURSNHS-UVJOBNTFSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 102000005862 Angiotensin II Human genes 0.000 description 5
- 101800000733 Angiotensin-2 Proteins 0.000 description 5
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 5
- 229950006323 angiotensin ii Drugs 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 238000005056 compaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 108010033243 lisinopril drug combination hydrochlorothiazide Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229940063159 zestoretic Drugs 0.000 description 4
- 238000004438 BET method Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000208011 Digitalis Species 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 201000003099 Renovascular Hypertension Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- -1 other polymorphs Chemical compound 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 229920003133 pregelled starch Polymers 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 229940088953 prinivil Drugs 0.000 description 1
- 229940117265 prinzide Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- Lisinopril is a drug on which extensive clinical experience has been obtained. It is currently sold in the United States under the trademark ZESTRIL® by AstraZeneca or PRINIVIL® by Merck & Co. A combination of lisinopril and hydrochlorothiazide is sold under the trademarks ZESTORETIC® by AstraZeneca or PRINZIDE® by Merck & Co. ZESTRIL® and ZESTORETIC® are manufactured by wet granulation tabletting using milled DCPD.
- a typical lisinopril formulation consists of lisinopril dihydrate, which can be any dose from 1mg-100 mg, the fillers (diluents)-dibasic calcium phosphate dihydrate and mannitol, maize starch as a binder and disintegrant and magnesium stearate as a lubricant.
- Lisinopril is a peptidyl dipeptidase inhibitor useful in treating cardiovascular diseases and disorders, such as hypertension and congestive heart failure (CHF) in mammals and especially in man. It inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion.
- ACE angiotensin converting enzyme
- ACE is known to be present in the endothelium and increased ACE activity in diabetic patients which results in the formation of angiotensin II and destruction of bradykinin, potentiates the damage to the endothelium caused by hyperglycaemia.
- ACE inhibitors including lisinopril, inhibit the formation of angiotensin II and breakdown of bradykinin and hence ameliorate endothelial dysfunction.
- Dibasic calcium phosphate dihydrate (DCPD, CaHPO 4 .2H 2 O) is a diluent used in tablet and capsule formulations. It is used both as an excipient (diluent/filler) and as a source of calcium in nutritional supplements. It is used in pharmaceutical products because of its compaction properties, and the good-flow properties, particularly the coarse-grade material.
- DCPD Dibasic calcium phosphate dihydrate
- Two main particle-size grades of DCPD are used in the pharmaceutical industry, milled and unmilled. The former material is typically used in wet-granulated or roller-compacted formulations whereas the latter coarse-grade material is typically used in dry, direct-compression formulations.
- dibasic calcium phosphate dihydrate Synonyms and trademarks for dibasic calcium phosphate dihydrate are: Cafos; calcium hydrogen orthophosphate dihydrate; calcium monohydrogen phosphate dihydrate; Calstar; Calipharm; dicalcium orthophosphate; Difos; DI-TAB; E341; Emcompress; phosphoric acid calcium salt (1:1) dihydrate; secondary calcium phosphate; calcium phosphate; and dicalcium phosphate, the latter two terms are commonly used generic terms in the pharmaceutical art.
- Dibasic calcium phosphate dihydrate is white, odourless, tasteless, nonhygroscopic and stable at room temperature. However, under certain conditions of temperature and humidity, it can lose water of crystallization below 100° C.
- lisinopril On long-term storage, when in the formulated product and particularly with low dosage formulations, lisinopril has a tendency to form diketopiperazine (DKP), a lisinopril degradation product or metabolite, which limits the shelf life for low dose formulations.
- DKP diketopiperazine
- the inventors have found a correlation between the amount and speed of DKP formation and the particle size of the co-formulated dibasic calcium phosphate dihydrate excipient.
- the present invention relates to a composition
- a composition comprising 1-(N 2 -[(S)-1-carboxy-3-phenylpropyl]-L-lysyl)-L-proline and processes for making the composition.
- 1-(N 2 -[(S)-1-carboxy-3-phenylpropyl]-L-lysyl)-L-proline is known under the generic name lisinopril.
- the novel composition is made with dibasic calcium phosphate dihydrate (DCPD, CaHPO 4 .2H 2 O) that possesses a low specific surface area of less than 1.5 m 2 g ⁇ 1 as determined by nitrogen adsorption (BET method).
- large-particle DCPD in a lisinopril formulation/composition has the effect of reducing the amount of the lisinopril degradation product diketopiperazine (DKP) that is formed, which would increase the shelf-life of tablets formulated with the large-particle DCPD, particularly those containing low dosage amounts of lisinopril.
- DKP diketopiperazine
- the lisinopril tablets formulated with large particle sized DCPD have a reduced tendency to form the lisinopril degradation product, diketopiperazine (DKP), particularly in low dosage lisinopril tablets.
- DKP diketopiperazine
- the invention is not limited by the tabletting method.
- the large particle DCPD can be used to form lisinopril tablets by either the previously employed wet-granulated method or by a dry, direct-compression method, of the same type, familiar to those skilled in the art, that is used for other products.
- the amount of large particle DCPD can be as low as 30% (w/w) of the tablet to obtain the benefit of the invention.
- a solid pharmaceutical composition comprising lisinopril, and an excipient, which comprises DCPD with a specific surface area of less than 1.5 m 2 g ⁇ 1 prior to compaction or tabletting in an amount that is at least 30% (w/w) of the composition.
- a tablet produced by either wet granulation tabletting or dry direct-compression tabletting comprising lisinopril, and an excipient, comprising lisinopril and an excipient which comprises DCPD with a specific surface area of less than 1.5 m 2 g ⁇ 1 prior to tabletting in an amount that is at least 30% (w/w) of the composition.
- a tablet comprising lisinopril, an excipient comprising mannitol and DCPD, magnesium stearate, and maize starch.
- a pharmaceutical composition in tablet form containing an amount of lisinopril selected from 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg wherein the amount of lisinopril is expressed as the weight of anhydrous lisinopril (e.g. 30 mg Zestril tablets contain 32.67 mg of lisinopril dihydrate).
- the dibasic calcium phosphate dihydrate has a specific surface area of less than 1.5 m 2 g ⁇ 1 , more preferably less than 1.25 m 2 g ⁇ 1 , still more preferably less than 0.9 m 2 g ⁇ 1 , even still more preferably less than 0.5 m 2 g ⁇ 1 .
- the indicated specific surface area refers the specific surface area prior to any compaction or compression that is performed during tabletting.
- the dibasic calcium phosphate dihydrate used in the invention has a specific surface area within the range of 0.2 and 1.5 m 2 g ⁇ 1 , preferably between 0.3 m 2 g ⁇ 1 and 0.9 m 2 g ⁇ 1 .
- the amount of DCPD is at least 50% (w/w) of the tablet, at least 60% (w/w) of the tablet and in the range of from 50% (w/w) to 70% (w/w) of the tablet.
- the excipient can further comprise at least 10% (w/w) mannitol.
- the reduced amount of lisinopril degradation product is believed to be due to the reduced specific surface area of the DCPD diluent. Accordingly, it will be appreciated that the invention is not restricted to the situation wherein substantially all of the DCPD is within a narrow (but large) size range, but also covers large and small particle size mixtures of DCPD that possess the desired specific surface area. Such mixtures could, for example be formed by combining milled and unmilled DCPD.
- the SSA limitation is a measure of the total surface area which can therefore accommodate mixtures.
- the lisinopril used according to the invention is lisinopril dihydrate.
- other solid forms of lisinopril such as other polymorphs, solvates or monohydrates are also contemplated.
- any form we include, solvated and desolvated forms, crystalline forms and amorphous forms.
- the present invention relies on the use of grades of DCPD that are commonly used in direct compression techniques thus, individuals or companies interested in preparing lisinopril tablets which routinely practice direct compression/compaction or dry granulation techniques, will particularly benefit from the present invention.
- the inventors have discovered that the 2.5 mg dosage tablets of lisinopril are susceptible to less DKP formation over time when DCPD with a lower specific surface area (SSA) than that conventionally used for wet granulation is used. It will be appreciated therefore, that because of the reduced propensity of the DCPD to dehydrate, there will be potential improvements in shelf-life of lisinopril tablets made with DCPD with a specific surface area less than 1.5 m 2 g ⁇ 1 , particularly of low dosage tablets such as 5 mg or 2.5 mg.
- SSA specific surface area
- enhanced stability of 2.5 mg tablets of lisinopril comprising using or incorporating dibasic calcium phosphate dihydrate with a specific surface area of less than 1.5 m 2 g ⁇ 1 .
- This can be effected by substituting unmilled DCPD for the conventionally used, milled DCPD.
- stable refers to the tendency to remain substantially in the same physical form for at least 6 months, more preferably at least a year, still more preferably at least 3 years, even still more preferably at least 5 years, when stored under ambient conditions (25° C./60%RH) without external treatment.
- the invention relies on the use of dibasic calcium phosphate with a specific surface area of less than 1.5 m 2 g ⁇ 1 .
- dibasic calcium phosphate with a specific surface area of less than 1.5 m 2 g ⁇ 1 .
- Some manufacturers of dibasic calcium phosphate will be able to provide the desired SSA of the product on demand.
- the SSA of dibasic calcium phosphate dihydrate can be determined by the BET method using nitrogen adsorption in a Micromeritics Flowsorb II (Bunauer et al., (1938) J. Am. Chem. Soc., 60:309-319).
- ‘Zestril’ is indicated in the treatment of essential hypertension and in renovascular hypertension. It may be used alone or concomitantly with other classes of antihypertensive agents.
- ‘Zestril’ is indicated in the management of congestive heart failure as an adjunctive treatment with diuretics and, where appropriate, digitalis. High doses reduce the risk of the combined outcomes of mortality and hospitalization.
- ‘Zestril’ is indicated for the treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction, to prevent the subsequent development of left ventricular dysfunction or heart failure and to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers.
- ‘Zestril’ reduces urinary albumin excretion rate. ‘Zestril’ reduces the risk of progression of retinopathy in normotensive insulin-dependent diabetes mellitus patients.
- a pharmaceutical composition comprising lisinopril, as active ingredient, in association with a pharmaceutically acceptable carrier, diluent or excipient and optionally other therapeutic ingredients, produced by a process comprising admixing lisinopril and DCPD with a specific surface area of less than 1.5 m 2 g ⁇ 1 .
- compositions comprising other therapeutic ingredients are especially of interest in the treatment of hypertension, congestive heart failure, acute myocardial infarction and in renal and retinal complications of diabetes mellitus.
- the invention also provides the use of lisinopril and dibasic calcium phosphate dihydrate with a specific surface area less than 1.5 m 2 g ⁇ 1 in the manufacture of a medicament for use in the treatment of a cardiovascular related condition, and in particular, a method of treating a hypertensive or congestive heart failure condition which method comprises administering to a subject suffering from said condition a therapeutically effective amount of a lisinopril composition produced by a process comprising admixing lisinopril and DCPD with a specific surface area of less than 1.5 m 2 g ⁇ 1 .
- the invention also provides a pharmaceutical composition
- lisinopril produced by a process comprising admixing lisinopril and DCPD with a specific surface area of less than 1.5 m 2 g ⁇ 1 , for use in treating hypertension, congestive heart failure, acute myocardial infarction and in renal and retinal complications of diabetes mellitus.
- the invention also provides the use of a lisinopril composition produced by a process comprising admixing lisinopril and DCPD with a specific surface area of less than 1.5 m 2 g ⁇ 1 in treating hypertension, congestive heart failure, acute myocardial infarction and in renal and retinal complications of diabetes mellitus.
- Any suitable route of administration may be employed for providing the patient with an effective dosage of drug comprising lisinopril according to the invention.
- peroral or parenteral formulations and the like may be employed.
- Dosage forms include capsules, tablets, dispersions, suspensions and the like, e.g. enteric-coated capsules and/or tablets, capsules and/or tablets containing enteric-coated pellets of lisinopril.
- lisinopril can be mixed with other suitable constituents.
- One route of administration is peroral using fast melt tablets.
- compositions of the invention comprise the compound of the invention.
- the compositions may be conveniently presented in unit dosage forms, and prepared by any methods known in the art of pharmacy.
- the most suitable route of administration as well as the magnitude of a therapeutic dose of a pharmaceutical composition comprising lisinopril according to the present invention will depend on the nature and severity of the disease to be treated.
- the dose, and dose frequency may also vary according to the age, body weight, and response of the individual patient.
- a suitable oral dosage form may cover a dose range from 0.5 mg to 150 mg total daily dose, administered in one single dose or equally divided doses.
- a preferred dosage range is from 1 mg to 60 mg.
- Combination therapies comprising lisinopril according to the present invention and other active ingredients in separate dosage forms, or in one fixed dosage form, may also be used.
- active ingredients include anti-bacterial compounds, non-steroidal anti-inflammatory agents, antacid agents, alginates, prokinetic agents, other antihypertensive agents, diuretics, digitalis, thrombolytics, aspirin and beta-blockers.
- Lisinopril tablets (2.5 mg) were prepared with various types of DCPD according to standard wet granulation methods.
- the enhanced stability correlating with an increase in particle size, is due to particle shape of the primary particles, and is as a result of the crystal structure of DCPD.
- the crystal structure of DCPD consists of compact sheets composed of parallel chains in which calcium ions are coordinated by six oxygen atoms of the anions and by two oxygen atoms of the dihydrate waters (Curry and Jones. (1971) J. Chem. Soc A. 23:3725-3729). Two sheets form layers with water interacting between the sheets, this layer like structure is reflected in the plate like morphology of the crystals. Dehydration takes place through the edges of the plate and therefore milling the larger plates increases the surface area available for loss of water resulting in faster dehydration as particle size is reduced.
- the stability of DCPD can be assessed by thermograviametric analysis (TGA).
- TGA thermograviametric analysis
- the determination of the onset for dehydration of DCPD can be used as an indicator of the chemical stability of lisinopril in the formulation. The higher the temperature of dehydration of the first loss of water of DCPD then the more stable is the formulated product. Data for a number of sources of DCPD is shown in Table 2.
- the specific surface area of DCPD is determined by the BET method using nitrogen adsorption in a Micromeritics Flowsorb II. Samples were first degassed under a vacuum at 50° C. for 24 hours.
- Thermogravimetric analysis (TGA, Mettler TG50) was carried out on samples (10-30 mg) over a temperature range of 25-300 ° C. and heating at 10 ° C. min ⁇ 1 using a nitrogen purge (100 ml min ⁇ 1 )
- Typical tablet formulations consist of:
- a drug (ranging from 1% -50%)
- a filler (excipient, diluent), which typically can be dibasic calcium phosphate dihydrate or microcrystalline cellulose or lactose or mannitol;
- a binder which typically can be polyvinylpyrrolidone (PVP) or hydroxy propyl methyl cellulose (HMPC) or microcrystalline cellulose or pre-gelled starch;
- PVP polyvinylpyrrolidone
- HMPC hydroxy propyl methyl cellulose
- microcrystalline cellulose pre-gelled starch
- a disintegrant which typically can be crosscarmellose sodium or sodium starch glycolate or starch;
- a lubricant which typically can be magnesium stearate and/or a glidant which is typically talc.
- a typical formulations containing lisinopril or lisinopril and hydrochlorothiazide as the drug (in amounts ranging from 0.5 mg-50 mg) consists of large particle size dibasic calcium phosphate dihydrate as the major excipient, which can be 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% of the total tablet weight or any amount within the range of 30-95% of the total tablet weight.
- the invention is particularly appropriate to lisinopril compositions (such as tablets) that comprise an amount of DCPD that is at least 30%, and preferably at least 50%, of the total composition (i.e. tablet) weight. Tablets that comprise DCPD as the main diluent in an amount of at least 50% of the total tablet weight are particularly preferred.
- compositions of specific formulations that are suitable for the present invention can be found in Bavitz, J. F., and Shiromani, P. K., 1986, Drug Dev. Ind. Pharm. 12, 2481-92 and in Shiromani, P. K., and Bavitz, J. F., 1988, Drug Dev. Ind. Pharm. 14, 1375-87.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
TABLE 1 |
Formation of diketopiperazine (DKP) in Zestril 2.5 mg formulation at |
50° C. with different specific surface areas (SSA) of Dibasic Calcium |
Phosphate Dihydrate (DCPD) |
SSA | DKP (%) | DKP (%) | |||
Source of DCPD | (m2g−1) | 1 month | 2 month | ||
Unmilled Calipharm | 0.40 | 0.50 | 0.97 | ||
Kyowa | 0.85 | 0.54 | 1.57 | ||
Milled Calipharm | 1.79 | 1.16 | 2.00 | ||
TABLE 2 |
The effect of source of dibasic calcium phosphate dihydrate and the |
relationship between specific surface area (SSA) and the onset of the |
first water loss as measured by TGA. |
SSA | Onset for first water loss | |||
Source of DCPD | (m2g−1) | (° C.) | ||
Emcompress | 0.36 | 74.7 | ||
Calipharm (unmilled) | 0.40 | 72.1 | ||
Calipharm (milled) | 1.79 | 56.6 | ||
Monsanto | 1.87 | 65.5 | ||
Stauffer | 2.10 | 59.2 | ||
TABLE 3 |
Typical tablet formulations containing 1 and 50% drug |
Ingredients | % (w/w) | % (w/w) | ||
Drug | 1 | 50 | ||
Filler | 88 | 29 | ||
Binder | 5 | 10 | ||
Disintegrant | 5 | 10 | ||
Lubricant | 1 | 1 | ||
Claims (12)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/962,429 US6462022B1 (en) | 2001-09-24 | 2001-09-24 | Lisinopril compositions having large-particle DCPD |
GB0311750A GB2384429B (en) | 2001-09-24 | 2002-09-20 | Lisinopril compositions having large-particle DCPD |
JP2003530259A JP4084749B2 (en) | 2001-09-24 | 2002-09-20 | Lisinopril composition with large particle DCPD |
PT02758654T PT1432407E (en) | 2001-09-24 | 2002-09-20 | LISINOPRIL COMPOSITIONS THAT MAY HAVE BIG PARTICLE DCPD |
EP02758654A EP1432407B2 (en) | 2001-09-24 | 2002-09-20 | Lisinopril compositions having large-particle dcpd |
ES02758654T ES2236561T5 (en) | 2001-09-24 | 2002-09-20 | Lysinopril compositions that have large particle DCPD. |
DK02758654T DK1432407T3 (en) | 2001-09-24 | 2002-09-20 | Lisinopril preparations having DCPD with large particles |
PCT/GB2002/004292 WO2003026622A1 (en) | 2001-09-24 | 2002-09-20 | Lisinopril compositions having large-particle dcpd |
AT02758654T ATE290370T1 (en) | 2001-09-24 | 2002-09-20 | PREPARATIONS WITH LISINOPRIL AND UNGROUND DCPD |
DE60203192T DE60203192T3 (en) | 2001-09-24 | 2002-09-20 | PREPARATIONS WITH LISINOPRIL AND UNBELIEVED DCPD |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/962,429 US6462022B1 (en) | 2001-09-24 | 2001-09-24 | Lisinopril compositions having large-particle DCPD |
Publications (1)
Publication Number | Publication Date |
---|---|
US6462022B1 true US6462022B1 (en) | 2002-10-08 |
Family
ID=25505851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/962,429 Expired - Lifetime US6462022B1 (en) | 2001-09-24 | 2001-09-24 | Lisinopril compositions having large-particle DCPD |
Country Status (10)
Country | Link |
---|---|
US (1) | US6462022B1 (en) |
EP (1) | EP1432407B2 (en) |
JP (1) | JP4084749B2 (en) |
AT (1) | ATE290370T1 (en) |
DE (1) | DE60203192T3 (en) |
DK (1) | DK1432407T3 (en) |
ES (1) | ES2236561T5 (en) |
GB (1) | GB2384429B (en) |
PT (1) | PT1432407E (en) |
WO (1) | WO2003026622A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196477A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly dissolving tablets comprising low surface area calcium phosphates |
WO2017077425A1 (en) | 2015-11-07 | 2017-05-11 | Ftf Pharma Private Limited | Oral solution of ace inhibitors |
WO2021175755A1 (en) | 2020-03-03 | 2021-09-10 | Alkaloid Ad Skopje | Formulation of lisinopril and amlodipine |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4925835B2 (en) | 2007-01-12 | 2012-05-09 | 日東電工株式会社 | Substance detection sensor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
US4675188A (en) * | 1985-08-02 | 1987-06-23 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
US4707361A (en) * | 1985-08-02 | 1987-11-17 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
US6117451A (en) * | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
US6210715B1 (en) * | 1997-04-01 | 2001-04-03 | Cap Biotechnology, Inc. | Calcium phosphate microcarriers and microspheres |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU222489B1 (en) † | 1990-07-25 | 2003-07-28 | Novartis Ag. | Stabilized pharmaceutical compositions and process for producing them |
-
2001
- 2001-09-24 US US09/962,429 patent/US6462022B1/en not_active Expired - Lifetime
-
2002
- 2002-09-20 DK DK02758654T patent/DK1432407T3/en active
- 2002-09-20 EP EP02758654A patent/EP1432407B2/en not_active Expired - Lifetime
- 2002-09-20 PT PT02758654T patent/PT1432407E/en unknown
- 2002-09-20 JP JP2003530259A patent/JP4084749B2/en not_active Expired - Fee Related
- 2002-09-20 ES ES02758654T patent/ES2236561T5/en not_active Expired - Lifetime
- 2002-09-20 AT AT02758654T patent/ATE290370T1/en active
- 2002-09-20 GB GB0311750A patent/GB2384429B/en not_active Expired - Fee Related
- 2002-09-20 WO PCT/GB2002/004292 patent/WO2003026622A1/en active IP Right Grant
- 2002-09-20 DE DE60203192T patent/DE60203192T3/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
US4675188A (en) * | 1985-08-02 | 1987-06-23 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
US4707361A (en) * | 1985-08-02 | 1987-11-17 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
US6210715B1 (en) * | 1997-04-01 | 2001-04-03 | Cap Biotechnology, Inc. | Calcium phosphate microcarriers and microspheres |
US6117451A (en) * | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
Non-Patent Citations (10)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196477A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly dissolving tablets comprising low surface area calcium phosphates |
WO2017077425A1 (en) | 2015-11-07 | 2017-05-11 | Ftf Pharma Private Limited | Oral solution of ace inhibitors |
WO2021175755A1 (en) | 2020-03-03 | 2021-09-10 | Alkaloid Ad Skopje | Formulation of lisinopril and amlodipine |
Also Published As
Publication number | Publication date |
---|---|
DE60203192T3 (en) | 2012-12-27 |
PT1432407E (en) | 2005-05-31 |
GB2384429B (en) | 2004-04-14 |
ATE290370T1 (en) | 2005-03-15 |
EP1432407B1 (en) | 2005-03-09 |
EP1432407B2 (en) | 2012-08-01 |
GB2384429A (en) | 2003-07-30 |
JP2005504803A (en) | 2005-02-17 |
JP4084749B2 (en) | 2008-04-30 |
DE60203192T2 (en) | 2006-04-13 |
DK1432407T3 (en) | 2005-05-23 |
EP1432407A1 (en) | 2004-06-30 |
GB0311750D0 (en) | 2003-06-25 |
ES2236561T3 (en) | 2005-07-16 |
WO2003026622A1 (en) | 2003-04-03 |
ES2236561T5 (en) | 2012-10-30 |
DE60203192D1 (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6875446B2 (en) | Method for prophylaxis and/or treatment of thromboembolism | |
US5674885A (en) | Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes | |
US20070105894A1 (en) | Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor | |
US20130115288A1 (en) | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone | |
US20100247642A1 (en) | Stable pharmaceutical formulation for a dpp-iv inhibitor | |
EP3320903B1 (en) | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin | |
KR20180049510A (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone | |
TW202220642A (en) | Formulations of triphenyl calcilytic compounds | |
EP2698159A1 (en) | Pitavastatin-containing preparation and method for producing same | |
US6462022B1 (en) | Lisinopril compositions having large-particle DCPD | |
AU2011339150B2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
KR102022694B1 (en) | Pharmaceutical composition | |
KR20200073676A (en) | Solid dispersion comprising valsartan and sacubitril and pharmaceutical composition comrising same and method of preparation therof | |
EP1906931B1 (en) | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof | |
KR102486815B1 (en) | A pharmaceutical composition comprising NEP inhibitor and ARB, and method for preparing the same | |
KR20250090224A (en) | Composite formulation comprising sacubitril-valsartan and sglt-2 inhibitior | |
TW202428264A (en) | Solid dosage forms of a plasma kallikrein inhibitor | |
KR20240079115A (en) | Pharmaceutical composition comprising quetiapine | |
KR20250096941A (en) | Pharmaceutical formulation in the form of single tablet comprising pitavastatin and ezetimibe, and a process for the preparation thereof | |
KR20220077092A (en) | Composite formulation for oral administration comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxyl acid and a process for the preparation thereof | |
TR202019859A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING EMOXIPIN AND DONEPEZIL | |
EP1308160A1 (en) | Highly absorbable solid preparation | |
KR20030070594A (en) | Pharmaceutical compositions comprising amlodipine maleate | |
EP3398589A1 (en) | Pharmaceutical composite preparation | |
HK1056829A (en) | Highly absorbable solid preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SYNGENTA LIMITED, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:ZENECA LIMITED;REEL/FRAME:012607/0860 Effective date: 20001208 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBERTS, RONALD JOHN;BOWEN, DAVID BRANDON;REEL/FRAME:013282/0778;SIGNING DATES FROM 20021114 TO 20021125 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |